TELO · Telomir Pharmaceuticals, Inc.
$1.14
-0.05 (-4.20%)
At close · Aug 28
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report.”View the 10-Q filed Aug 13, 2026
Market Cap
$78.40M
Shares
68.77M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.14
Open$1.20
Day$1.14–1.20
52W close$0.92–1.93
Avg vol 30d82K
Short int814K · 1.2% float · 16.3d
Short vol20%
DataFeb 2024–Aug 2026
Filing10-Q · Aug 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
−4%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
22%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−14%
trailing
YTD return
−14%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+22% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.18% of float · ▼ -15.5% MoM · 16.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
33 holders — mid 2-yr range
Squeeze score
47
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
22%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+22% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.18% of float · ▼ -15.5% MoM · 16.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
33 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 22%
Range high $2
vs 200-day avg -11%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TELO
this stock
Telomir Pharmaceuticals, Inc.
|
$78.40M | -14.3% | — | — | 1.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TELO | +0.9% | -5.8% | -14.3% | -5.8% | -14.3% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +0.4% | -8.8% | -27.7% | -8.8% | -27.1% |